Treatment of Mycobacterium Xenopi Pulmonary Infection
France92 participantsStarted 2011-03-02
Plain-language summary
The purpose of this study is to determine the 6-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The patient and/or legal representative of the patient has provided a written informed consent before inclusion in the study
* The patient is aged 18 or older
* The patient has signs of functional respiratory (cough, sputum, hemoptysis, dyspnea, chest pain and / or general signs (asthenia and / or anorexia and / or weight loss)
* The patient has a creatinine clearance above 30 ml / min
* The patient underwent a thoracic scan not older than one month before the first positive bacteriological sample.
* The patient underwent a bronchoscopy with sampling conducted in the territory corresponding to the radiographic
* The most plausible alternative diagnostics have been eliminated using the thoracic scan and bronchoscopy
* The patient has at least two positive cultures for M. xenopi sputum collected on two separate days AND/OR a positive culture for M. xenopi in a bronchoalveolar lavage or bronchial aspiration directed AND / OR transbronchial biopsy or lung biopsy with surgical histology for a mycobacterial infection (granuloma or Ziehl positive) and a culture positive M. xenopi, AND / OR biopsy with histology compatible with mycobacteriosis and one or more positive sputum culture for M . xenopi
* The patient is willing and able to take the study treatment throughout the duration
* If this is a woman of childbearing age, the patient is ready to use for the duration of the test contraception method other than estrogen-progestin
* The patient did not participat…
What they're measuring
1
Sputum conversion at 6 months under three antibiotics treatment (Rifampin, ethambutol and a third drug clarithromycin or moxifloxacin)